Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights
Study Summary
This trial is testing a new drug to see if it is safe and effective in treating patients with a primary glomerular disease who have persistent proteinuria.
Eligible Conditions
- Proteinuria
- Glomerulonephritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage change in 24-hour urinary protein excretion at Week 12
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: 400 mg QDExperimental Treatment1 Intervention
400 mg of ANG-3070 will be taken once daily for 12 weeks
Group II: 300 mg BIDExperimental Treatment1 Intervention
300 mg of ANG-3070 will be taken twice a day for 12 weeks.
Group III: 200 mg QDExperimental Treatment1 Intervention
200 mg of ANG-3070 will be taken once daily for 12 weeks.
Group IV: PlaceboPlacebo Group1 Intervention
Placebo capsules will be taken once or twice daily for 12 weeks.
Find a Location
Who is running the clinical trial?
Angion Biomedica CorpLead Sponsor
11 Previous Clinical Trials
862 Total Patients Enrolled
John Neylan, MDStudy DirectorAngion Biomedica
3 Previous Clinical Trials
628 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger